Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

248
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
248
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

211
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
211
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

160
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
160
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

166
Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
166
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

141
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
141
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinician and Patient Perspectives on a Patient-Facing Online Breast Cancer Symptom Visualization Tool.

JCO clinical cancer informatics·2025
Same author

PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels.

Entropy (Basel, Switzerland)·2024
Same author

Visualizing hypothesis tests in survival analysis under anticipated delayed effects.

Pharmaceutical statistics·2024
Same author

High-resolution Diffusion-weighted Imaging to Detect Changes in Tumor Size and ADC, and Predict Adverse Biopsy Histology during Prostate Cancer Active Surveillance.

Cancer research communications·2024
Same author

Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?

Brazilian journal of biometrics·2024

Related Experiment Video

Updated: Jan 11, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K

A Bayesian design for dual-agent dose optimization with targeted therapies.

José L Jiménez1, Mourad Tighiouart2

  • 1Quantitative Safety and Epidemiology, Novartis Pharma A.G., Basel, Switzerland.

Journal of Biopharmaceutical Statistics
|November 17, 2025
PubMed
Summary

This study introduces a novel two-stage adaptive design for combining targeted cancer therapies. The method efficiently identifies optimal dose combinations by balancing treatment risks and benefits, improving upon existing algorithms for drug development.

Keywords:
Bayesian phase I-II designdose optimizationdrug combinationoncologytargeted therapies

More Related Videos

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

572
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Related Experiment Videos

Last Updated: Jan 11, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

572
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Area of Science:

  • Clinical trial design
  • Pharmacology
  • Biostatistics

Background:

  • Combination therapies, such as MEK and PIK3CA inhibitors, present challenges in dose selection.
  • Higher doses do not always correlate with improved efficacy in targeted therapies.
  • Optimizing the risk-benefit profile is crucial for effective treatment strategies.

Purpose of the Study:

  • To propose a novel two-stage phase I-II adaptive clinical trial design for molecularly targeted therapy combinations.
  • To identify optimal dose combinations that achieve a desirable risk-benefit trade-off.
  • To enhance the safety and efficiency of dose-finding studies in oncology.

Main Methods:

  • A two-stage design incorporating escalation with overdose control (EWOC) in Stage I.
  • Adaptive randomization in Stage II based on continuously updated model parameters.
  • Utilizing a flexible cubic spline model to represent efficacy response distributions.

Main Results:

  • The proposed design demonstrated superior safety and efficiency in simulations compared to existing algorithms.
  • The design effectively identifies optimal dose combinations for targeted therapy regimens.
  • Performance was evaluated across various scenarios, including sample size variations and model misspecification.

Conclusions:

  • The novel adaptive design offers a safer and more efficient approach for determining optimal dose combinations in targeted therapy trials.
  • This methodology facilitates better risk-benefit assessment in complex drug development settings.
  • The design is robust and adaptable to different clinical trial parameters and modeling assumptions.